The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study

Sara Harsini1, Heather Saprunoff1, Tina Alden1, Behnoud Mohammadi1, Don Wilson1, and François Bénard1,2

1BC Cancer, Vancouver, British Columbia, Canada; and 2Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada

The prostate-specific membrane antigen (PSMA) is an excellent target for theranostic applications in prostate cancer. However, PSMA-targeted radioligand therapy can cause undesirable effects due to high accumulation of PSMA radiotracers in salivary glands and kidneys. This study assessed orally administered monosodium glutamate (MSG) as a potential means of reducing kidney and salivary gland radiation exposure using a PSMA-targeting radiotracer.

Methods: This prospective, double-blind, placebo-controlled study enrolled 10 patients with biochemically recurrent prostate cancer. Each subject served as his own control. PET/CT imaging sessions using 2-[3-(1-carboxy-5-[6-18F-fluoro-pyridine-3-carbonyl]-amino)-pentyl]-ureido)pentanedioic acid (18F-DCFPyL) were performed 3–7 d apart, after oral administration of either 12.7 g of MSG or placebo. Data from the 2 sets of images were analyzed by placing regions of interest on lacrimal, parotid, and submandibular glands; left ventricle; liver; spleen; kidneys; bowel; urinary bladder; gluteus muscle; and malignant lesions. The results from MSG and placebo scans were compared by paired analysis of the region-of-interest data. Results: In total, 142 pathologic lesions along with normal tissues were analyzed. As hypothesized a priori, there was a significant decrease in SUVmax corrected for lean body mass (SULmax) on images obtained after MSG administration in the parotids (24% ± 14%, P = 0.001), submandibular glands (35% ± 11%, P < 0.001), and kidneys (23% ± 26%, P = 0.014). Significant decreases were also observed in the lacrimal glands (49% ± 13%, P < 0.001), liver (15% ± 6%, P < 0.001), spleen (28% ± 13%, P = 0.001), and bowel (44% ± 13%, P < 0.001). A mildly lower blood pool SULmean was observed after MSG administration (decrease of 11% ± 13%, P = 0.021). However, significantly lower radiotracer uptake in terms of SULmean, SULpeak, and SUVmax was observed in malignant lesions on scans performed after MSG administration than on the placebo studies (SULmax median decrease, 33%; range, –1% to 75%; P < 0.001). No significant adverse events occurred after placebo or MSG administration, and vital signs were stable. Conclusion: Orally administered MSG significantly decreased salivary gland, kidney, and other normal-organ PSMA radiotracer uptake in human subjects, using 18F-DCFPyL as an exemplar. However, MSG caused a corresponding reduction in tumor uptake, which may limit the benefits of this approach for diagnostic and therapeutic applications.

Key Words: monosodium glutamate; PSMA; prostate-specific membrane antigen; salivary glands; kidney

DOI: 10.2967/jnumed.120.246983

Prostate cancer (PCa) is the principal cause of cancer mortality in men worldwide because of the development of metastatic disease (1). Advanced stages of PCa initially respond to androgen deprivation therapy, but within an interval of 1–3 y, they invariably develop androgen independence (2). Other therapeutic agents approved for the treatment of metastatic castration-resistant PCa (cabazitaxel (3), abiraterone (4), sipuleucel-T (5), enzalutamide (6), and 223Ra (7)) can improve survival. However, none culminated in durable clinical responses, with a survival benefit of generally less than 6 mo (6). The prostate-specific membrane antigen (PSMA), a type II carboxypeptidase-associated transmembrane glycoprotein with a folate hydrolase activity, is overexpressed in PCa cells (8). Several radiolabeled PSMA ligands, showing high sensitivity or specificity for PSMA-expressing tissues, have been investigated in PET imaging (9). Current evidence suggests that PSMA-targeting radioligand therapy (RLT) shows promise to treat metastatic castration-resistant PCa patients, by using ligands such as β-emitting (177Lu) or α-emitting isotopes (223Ac) (10,11).

One of the major disadvantages of PSMA-RLT is the high accumulation of the radiolabeled tracers in nontarget organs, including the salivary glands and kidneys. High accumulation of the PSMA radiopharmaceuticals in salivary glands can result in transient or permanent xerostomia, an adverse event with a variable reported rate of 8%–87%, which is particularly problematic with 223Ac, leading to treatment discontinuation in many cases (10,12). On the other hand, renal accumulation of β-emitters such as 177Lu-PSMA-617 represents the cumulative dose-limiting toxicity and leads to risk of nephrotoxicity (13). Furthermore, the increased risk of chronic renal disease prevents initiation of PSMA-RLT earlier in the disease course (14). Many attempts—including sialendoscopy with dilatation, saline irrigation, steroid injection, intraparenchymal injections of botulinum toxin, external cooling of the salivary glands with ice packs, and oral administration of folic polyglutamate tablets—have been tried to mitigate salivary gland toxicity, with some, but limited, success (15–18). Mannitol infusion is a strategy...
to reduce renal uptake of PSMA-targeted tracers by acting as an osmotic diuretic, decreasing renal reabsorption. However, its effect on tumor uptake needs to be clarified (19). The administration of 2- (phosphonomethyl)pentane-1,5-dioic acid (2-PMPA), a phosphonate-based PSMA inhibitor, reduced accumulation of PSMA radiotracers in the kidneys in a dose-dependent manner, but this reduction was generally accompanied by decreased tumor uptake (20–22). A novel 2-PMPA prodrug (e.g., tris-POC-2-PMPA) has been proposed to specifically shield the kidneys and salivary glands from PSMA-RLT; however, its effect on tumor uptake requires further studies (23).

We recently reported that the administration of monosodium glutamate (MSG), a well-known food additive, reduced salivary and kidney 
\(^{68}\text{Ga-PSMA-11}\) uptake in LNCap tumor-bearing mice while leaving tumor uptake unaffected (24).

In this study, we explored the effects of MSG in human subjects on the biodistribution of a PSMA-targeting radiopharmaceutical. We performed an intraindividual comparison of the biodistribution of 2-3-(1-carboxy-5-[(6-\(^{18}\text{F-fluoro-pyridine-3-carbonyl)-amino-pentyl}-ureido)-pentanedioic acid (\(^{18}\text{F-DCFPyL}\)) in patients with biochemical recurrence of PCa, comparing scans performed with the prior administration of orally administered MSG or placebo. We evaluated the uptake of \(^{18}\text{F-DCFPyL}\) in normal organs and malignant lesions to determine whether MSG could reduce off-target binding of PSMA-targeting radiopharmaceuticals as a potential strategy to improve the therapeutic ratio of RLT.

MATERIALS AND METHODS

Patients

The study included 10 patients with either of the following criteria: known PCa with biochemical recurrence after initial curative radiation therapy, with a prostate-specific antigen level of more than 2 ng/mL above the nadir after therapy, or known PCa with biochemical recurrence after initial curative radical prostatectomy, with a prostate-specific antigen level of more than 0.4 ng/mL and an additional measurement showing increase. Exclusion criteria were medical instability; inability to lie supine for imaging; inability to provide written consent; a body weight exceeding the safe limit of the PET/CT bed (204.5 kg) or an inability to fit through the PET/CT bore (70-cm diameter); an Eastern Cooperative Oncology Group status of more than 2; severe uncontrolled hypertension; a history of severe asthma; a history of intolerance to MSG; a history of severe headaches or migraines triggered by food or MSG; and use of a sodium- or salt-restricted diet due to other medical conditions. Although no treatment was discontinued before the \(^{18}\text{F-DCFPyL}\) scan, no new treatment was initiated between the first and second \(^{18}\text{F-DCFPyL}\) scans. The patients were randomly assigned to receive either placebo or MSG before the first PET acquisition and then crossed over to the other intervention for a repeat scan within 3–7 d. The patients, research staff acquiring the studies, and scan readers did not know whether the subjects received placebo or MSG.

The study was approved by the University of British Columbia/BC Cancer Research Ethics Board. Written informed consent was provided by all participants before inclusion in the study. The study was registered on ClinicalTrials.gov (NCT03693742).

Study Procedures

Patient demographics, relevant oncologic history, laboratory values, and tumor pathology data were recorded. Participants were followed up 24 h after radiotracer administration to identify adverse events. \(^{18}\text{F-DCFPyL}\) was synthesized according to a previously published method (25). The administered activity was scaled by body weight (range, 237–474 MBq), allowing a 10% variation in target activity. After a 4-h fast and 30 min before intravenous \(^{18}\text{F-DCFPyL}\) injection, each participant ingested either 300 mL ± 5% of low-sodium tomato juice (Heinz) containing 12.7 g of MSG or regular tomato juice (Heinz; placebo), according to a computer-generated random list that determined the sequence of the scans. Second PET/CT examinations were performed within an interval of 3–7 d.

Vital signs were recorded before administration of MSG, before \(^{18}\text{F-DCFPyL}\) injection, between 5 and 15 min after \(^{18}\text{F-DCFPyL}\) injection, and 60 min after radiotracer injection. Between 60 and 120 min, participants were allowed to have a meal of their choice. After a 120-min uptake period, vital signs were monitored again, and the participants were imaged from the top of the head to the mid thigh on a Discovery PET/CT 690 scanner (GE Healthcare). A CT scan for localization and attenuation correction (120 kV; automatic mA selection [30–200 mA range], and noise index of 20) was acquired. PET data were acquired immediately after the CT scan over 2–4 min/bed position, adjusted for participant girth. All images were reconstructed identically using ordered-subset expectation maximization and point-spread function modeling.

Image Interpretation

Two nuclear medicine physicians with access to all clinical data reviewed the PET/CT images reconstructed without the time-of-flight option using a MIM workstation (MIM Maestro, version 6.9.4; MIM Software Inc.). PET, CT, and PET/CT images were reviewed in axial, coronal, and sagittal planes in 2 reading sessions. The readers did not know which intervention occurred before the scan they were interpreting (MSG or control). After visual qualitative identification of the tumoral lesions, a semiquantitative evaluation was performed on the basis of SUV adjusted for the lean body mass and reflecting a maximum single-pixel uptake value (SUL\(_{\text{max}}\)); SUL\(_{\text{peak}}\), calculated using an automated computed maximal average SUV in a 1.0 cm\(^3\) spheric volume within the tumor; and SUL\(_{\text{mean}}\). For normal organs, regions of interest were drawn at predetermined reference sites, including the lacrimal, parotid, and submandibular glands; left ventricular blood pool; liver; spleen; kidneys; bowel; urinary bladder; and gluteus muscle. The arithmetic mean was calculated for paired organs. For all malignant lesions, the SUL\(_{\text{max}}\), SUL\(_{\text{mean}}\) and SUL\(_{\text{peak}}\) were measured using the PET Edge tool running on MIM. All regions of interest were created in 1 dataset by a masked observer and then saved and compared with the identical location in the second dataset for matched comparisons of activity.

Statistical Analysis

Descriptive values were expressed as the mean ± SD or as the median and range if data were not normally distributed according to the Shapiro–Wilks test. The relative percentages of SUL\(_{\text{max}}\), SUL\(_{\text{mean}}\), and SUL\(_{\text{peak}}\) change between control and MSG studies were calculated as [(MSG value – control value)/control value] × 100. The independent Student t test was performed to compare normal variables; otherwise, nonparametric tests, including the Wilcoxon signed-rank test for paired data, were used to compare malignant lesion SUL\(_{\text{max}}\), SUL\(_{\text{mean}}\), and SUL\(_{\text{peak}}\). To adjust for multiple testing and control the false-discovery rate, the Benjamini–Hochberg method was used (26).

Finally, the sample was adjusted by a weight factor, using the weight-of-patient girth. All images were reconstructed identically using ordered-subset expectation maximization and point-spread function modeling.
RESULTS

Demographic Characteristics

As depicted in Table 1, this prospective analysis included 10 patients (mean age, 72 ± 4.5 y), of whom 6 had a biochemical recurrence after radical prostatectomy and 4 had a biochemical recurrence after curative-intent radiotherapy. Prior treatments included surgery (60% of cases), radiotherapy (90%), or androgen deprivation therapy (30%), with 60% of participants having received more than 1 type of therapy. Overall, the subjects had a mean prostate-specific antigen level of 6.62 ± 9.56 ng/mL, with a doubling time of 11.3 ± 12.2 mo (n = 9 mo).

Normal Tissues

The average SULmean and SULmax of different normal tissues in all patients for both MSG and control PET/CT are described in Table 2. A statistically significant lower SULmean in the MSG group than in the placebo group was noted in the left ventricle blood pool (10.72% ± 12.54%, P = 0.03), liver (15.75% ± 7.32%, P < 0.001), spleen (34.34% ± 11.11%, P = 0.001), parotid glands (26.07% ± 16.98%, P = 0.004), submandibular glands (34.68% ± 18.68%, P = 0.001), lacrimal glands (41.88% ± 18.88%, P < 0.001), bowel (45.08% ± 13.83%, P = 0.001), and kidneys (27.09% ± 12.07%, P = 0.001). The SULmax was lower in the liver (14.88% ± 18.59%, P = 0.001), spleen (28.79% ± 13.09%, P = 0.001), parotid glands (33.98% ± 14.03%, P < 0.001), submandibular glands (12.95% ± 14.60%, P = 0.001), and kidneys (25.46% ± 15.83%, P = 0.001). The lower SULmax in the left ventricle blood pool (10.72% ± 12.54%, P = 0.03), liver (15.75% ± 7.32%, P < 0.001), bowel (45.08% ± 13.83%, P = 0.001), and kidneys (27.09% ± 12.07%, P = 0.001) was statistically significant.

Table 1

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (y)</th>
<th>Weight (kg)</th>
<th>Height (cm)</th>
<th>TNM</th>
<th>Gleason score</th>
<th>Previous therapy</th>
<th>PSA value (ng/mL)</th>
<th>PSA doubling time (mo)</th>
<th>MSG dose (mg/kg)</th>
<th>Injected activity (MBq)</th>
<th>Uptake time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>73</td>
<td>72.3</td>
<td>160</td>
<td>pT3apN0M0</td>
<td>7 (3 + 4)</td>
<td>RP + RT + ADT</td>
<td>3.3</td>
<td>39.2</td>
<td>175.66</td>
<td>289.9</td>
<td>120</td>
</tr>
<tr>
<td>2</td>
<td>72</td>
<td>86.2</td>
<td>170</td>
<td>cT2acN0M0</td>
<td>7 (4 + 3)</td>
<td>RT</td>
<td>2.13</td>
<td>9.9</td>
<td>147.33</td>
<td>344.8</td>
<td>120</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>85.3</td>
<td>173</td>
<td>cT2ccN0M0</td>
<td>8</td>
<td>RT</td>
<td>4.67</td>
<td>3</td>
<td>148.89</td>
<td>366.2</td>
<td>120</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>76.6</td>
<td>181</td>
<td>cT2bcN0M0</td>
<td>7 (3 + 4)</td>
<td>RT</td>
<td>30</td>
<td>23.7</td>
<td>165.79</td>
<td>369.1</td>
<td>120</td>
</tr>
<tr>
<td>5</td>
<td>75</td>
<td>77.6</td>
<td>169</td>
<td>pT3apN0M0</td>
<td>7 (4 + 3)</td>
<td>RT</td>
<td>0.62</td>
<td>—</td>
<td>163.66</td>
<td>353</td>
<td>120</td>
</tr>
<tr>
<td>6</td>
<td>71</td>
<td>110.2</td>
<td>180</td>
<td>cT2cN0M0</td>
<td>7 (3 + 4)</td>
<td>RT + ADT</td>
<td>6.5</td>
<td>5.3</td>
<td>115.24</td>
<td>410.1</td>
<td>120</td>
</tr>
<tr>
<td>7</td>
<td>69</td>
<td>93</td>
<td>183</td>
<td>pT3bpN0M0</td>
<td>7 (4 + 3)</td>
<td>RT</td>
<td>0.93</td>
<td>3.2</td>
<td>136.56</td>
<td>354.2</td>
<td>120</td>
</tr>
<tr>
<td>8</td>
<td>76</td>
<td>92.3</td>
<td>172.5</td>
<td>pT3apN0M0</td>
<td>7 (4 + 3)</td>
<td>RT + RT</td>
<td>0.92</td>
<td>6.7</td>
<td>137.59</td>
<td>340.9</td>
<td>120</td>
</tr>
<tr>
<td>9</td>
<td>76</td>
<td>92.1</td>
<td>180</td>
<td>pT3apN0M0</td>
<td>7 (4 + 3)</td>
<td>RT + ADT</td>
<td>0.44</td>
<td>6.5</td>
<td>137.89</td>
<td>373</td>
<td>120</td>
</tr>
<tr>
<td>10</td>
<td>77</td>
<td>77.1</td>
<td>170</td>
<td>pT3bpN1M0</td>
<td>7 (3 + 4)</td>
<td>RT</td>
<td>16.72</td>
<td>4.2</td>
<td>164.72</td>
<td>354</td>
<td>120</td>
</tr>
</tbody>
</table>

PSA = prostate-specific antigen; RP = radical prostatectomy; RT = radiotherapy; ADT = androgen deprivation therapy.

PSMA Radiotracer Uptake

As depicted in Table 1, this prospective analysis included 10 patients (mean age, 72 ± 4.5 y), of whom 6 had a biochemical recurrence after radical prostatectomy (60% of cases), radiotherapy (90%), or androgen deprivation therapy (30%), with 60% of participants having received more than 1 type of therapy. Overall, the subjects had a mean prostate-specific antigen level of 6.62 ± 9.56 ng/mL, with a doubling time of 11.3 ± 12.2 mo (n = 9 mo). Representative MSG and control [18F]-DCFPyL PET/CT scans are shown in Figure 1.
of SUL\textsubscript{mean} and SUL\textsubscript{max} on PET/CT images being found for all patients after MSG administration than for control patients. The comparison between MSG and control SUL\textsubscript{max} is shown in Figure 2.

When the MSG amount was normalized to body weight, no significant dose–response relationship could be demonstrated for percentage changes in salivary gland and renal SUL\textsubscript{max} (Supplemental Fig. 1; supplemental materials are available at http://jnmm.jnm.org).

**Malignant Lesions**

At least 1 lesion characteristic of PCa was detected in each patient. Active disease was most often characterized in lymph nodes (67.6%), followed by bone (29.6%) and prostate bed or seminal vesicles (2.8%). Seven participants (70%) had disease in more than 1 site. Overall, 142 lesions were detected on both MSG and control images, with a significantly higher median SUL\textsubscript{peak} in the control group than in the MSG group, at 4.13 versus 3.01, respectively ($P$, 0.001), and a median SUL\textsubscript{mean} of 2.88 versus 1.57, respectively ($P$, 0.001), and a median SUL\textsubscript{max} of 4.36 versus 2.78, respectively ($P$, 0.001) (Table 3). The decrease was significant for local recurrences, lymph nodes, and osseous metastases (Fig. 3). All lesions were visible on both MSG and control images, with the exception of 2 osseous metastases that were visible on control images only.

**Adverse Events**

Regarding vital signs for the MSG group, blood pressure changed from 156.80 ± 12.03/92.20 ± 8.57 mm Hg before MSG administration to 154.90 ± 15.63/84.10 ± 7.63 mm Hg immediately before the scan; the respective values were 71.70 ± 10.67 bpm to 86.70 ± 12.31 bpm for heart rate and 97.90% ± 1.66% to 97.20% ± 1.87% for pulse oximetry. In the placebo group, blood pressure changed from 153.40 ± 18.66/90.60 ± 6.62 mm Hg before placebo administration to 151.80 ± 17.54/85.70 ± 7.21 mm Hg at 2 h after radiotracer administration.
injection; the respective values were 68.40 ± 7.95 bpm to 74.20 ± 11.07 bpm for heart rate and 98.20% ± 1.75% to 97.90% ± 1.52% for pulse oximetry. Except for heart rate in the MSG group, the differences in these values were not statistically significant. Heart rate alterations were considered clinically insignificant. There were no adverse events during the scans.

DISCUSSION

PSMA-targeting RLT is a promising treatment with a significant impact on PCa management (27–29). 177Lu- and 225Ac-labeled PSMA ligands have shown efficacy in metastatic castration-resistant PCa patients, but physiologic tracer uptake in salivary glands and kidneys can cause xerostomia and potential for nephrotoxicity (30,31). The fact that radiolabeled anti-PSMA antibodies have low uptake in these organs supports the hypothesis that beyond PSMA expression, the accumulation of small-molecule PSMA inhibitors could be partially attributed to off-target binding (32,33). Although this undesired uptake of PSMA ligands in normal PSMA-expressing organs does not hinder diagnostic interpretation, it imposes a limit on the maximum tolerable dose for PSMA-RLT. Notwithstanding the fact that xerostomia typically appears after the second or third cycle of PSMA-RLT, discontinuation of this mode of therapy has been reported in patients treated with α-emitters (34). Patients with late-stage, heavily pretreated, resistant metastatic castration-resistant PCAs constitute the main category of patients in whom these treatments have thus far been offered. The poor life expectancy of this group likely masks the emergence of late radiation-induced kidney failure, which generally requires 2 or more years to manifest (35). However, renal toxicity might become a more significant concern if PSMA-RLT were to be initiated in patients at an early stage of high-risk PCa with metastatic or oligometastatic disease (36). A protection approach to the meaningful mitigation of toxicities associated with PSMA radiotherapeutics would be useful to enable the broadest, earliest, and most effective use of these radiotherapeutics.

A few investigations have suggested protective approaches to mitigating PSMA radioligand accumulation in these organs. Rousseau et al. (24) reported that intraperitoneal injection of up to a 164 mg/kg dose of MSG in LNCap tumor–bearing NOD SCID γ (NSG) mice resulted in lower salivary and kidney uptake of 68Ga-PSMA-11 in a dose-dependent manner, whereas tumor uptake was unaffected. Considering the fact that most PSMA ligands integrate a glutamate moiety to bind to PSMA, it was postulated that the administration of MSG could act by blocking nonspecific binding in healthy organs (24).

Hillier et al. showed nearly complete blockade of tumor and kidney uptake of the PSMA inhibitor 125I-MIP-1095 after coinjection of 2-PMPA (37). The potential of 2-PMPA to selectively block kidney uptake without affecting LNCap tumor uptake was demonstrated by Kratochwil et al. through administration of 2-PMPA at 1 or 16 h after injection of the PSMA inhibitors 99mTc-MIP-1404 and 123I-MIP-1095, respectively (22). Chatalic et al. showed an improved tumor-to-kidney absorbed dose ratio by coinjection of 2-PMPA with 111In/177Lu-PSMA I&T, which was accompanied by a reduction in tumor uptake (27).

Among recently developed orally available prodrugs of 2-PMPA (23), JHU-2545 has been administered in a small number of metastatic castration-resistant PCa patients 15 min before injection of 177Lu-PSMA-617 and was found to increase the metastasis or salivary gland dose ratio to 350%–550% of control values and the metastasis or kidney dose ratio to between 190% and 650% of control. On the basis of the available dosimetry, Nedelcovych et al. concluded that this prodrug could increase the cumulative allowable 177Lu-PSMA-617 dose by 2- to 6-fold (38). Supported by favorable preclinical data obtained with 68Ga-PSMA-11, the present study aimed to assess orally administered MSG as a potential means of reducing normal-organ PSMA-targeting radiotracer uptake in human subjects. We observed a significant decrease in SULmax on images obtained after MSG administration in the parotids, submandibular glands, kidneys, lacrimal glands, liver, spleen, and bowel. A mildly lower blood pool SULmean was also observed after MSG administration. Hence, our results indicate that the uptake of 18F-DCFPyL in normal tissues was blocked.

### TABLE 3
Comparison of 18F-DCFPyL Uptake in Malignant Lesions for Control and MSG Studies

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control study (n = 142)</th>
<th>MSG study (n = 140)</th>
<th>Decrease (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>SULmax</td>
<td>4.4 [1.1, 30.3]</td>
<td>2.8 [0.7, 23.4]</td>
<td>32.8 [−1.3, 74.5]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SULmean</td>
<td>2.9 [0.9, 17.1]</td>
<td>1.6 [0.6, 14.5]</td>
<td>29.1 [0.0, 73.5]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SULpeak</td>
<td>4.1 [0.7, 21.1]</td>
<td>3.0 [0.5, 16.8]</td>
<td>30.1 [−46.6, 71.6]</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

All values are statistically significant at α = 0.05 level. Data are median followed by range in brackets.
by the administration of MSG, with the highest effect being noted in the lacrimal glands, followed by the colon. However, radiotracer uptake in malignant lesions was unfortunately lower on scans performed after MSG administration than on placebo scans.

The findings of this study are in line with our previously reported preclinical results, except for the decrease in malignant prostate lesions, which was not observed in tumor-bearing mice in the study conducted with $^{68}$Ga-PSMA-11. Roy et al. recently performed an $^{18}$F-DCEFPyL autoradiography and biodistribution study in human, mouse, rat, cynomolgus, and rhesus species and indicated that the binding affinity of $^{18}$F-DCEFPyL for PSMA was similar across the tested species, although the PSMA expression levels varied. The human submandibular gland exhibited approximately 2-fold lower PSMA expression than the baboon submandibular gland, whereas rodents showed the lowest PSMA levels, with mice being 10-fold higher than rats. Cynomolgus and rhesus monkeys had 2- to 3-fold lower submandibular gland PSMA levels than humans (39). Differences in PSMA expression patterns between human organs and their murine homologs, differences in relative binding affinities between $^{68}$Ga-PSMA-11 and $^{18}$F-DCEFPyL, and differences in the pharmacokinetic properties of MSG absorption and clearance between mice and humans may contribute to the differences noted between murine and human studies.

All except 2 lesions were visible on our MSG images; the sample size was not designed to assess the impact of MSG administration on the diagnostic sensitivity for PET imaging. This study aimed at evaluating the potential for MSG to reduce activity retention in the kidneys and salivary glands, with the perspective of eventually using a similar approach for RLT. The choice of a diagnostic rather than therapeutic radiopharmaceutical was made for ethical reasons, to avoid compromising a potentially beneficial therapy with an intervention of unknown benefit.

At the oral doses we used in this study, no significant adverse events occurred after the administration of MSG. MSG is a widely studied food additive, with an excellent track record of safety (40). As an orally administered condiment, it would have been an ideal candidate compound for kidney and salivary gland protection because of its low cost, widespread availability, and low toxicity.

CONCLUSION

Our study showed that oral administration of MSG significantly reduced $^{18}$F-DCEFPyL uptake in salivary glands, kidneys, and other normal organs in human subjects. However, MSG also caused a corresponding decrease in tumor uptake, which limits the benefits of this approach for enhancing the therapeutic ratio of PSMA-RLT. Efforts to further improve our understanding of the mechanisms of PSMA radioligands in normal organs may result in more effective preventive and therapeutic strategies. Further investigations are warranted to identify compounds capable of selectively blocking both specific and nonspecific binding of PSMA radioligands in the salivary glands and kidneys to protect these organs without affecting tumor uptake.

DISCLOSURE

This study was performed with the financial support of the BC Cancer Foundation, CIHR grant FDN-148465, and the BC Leadership Chair in Functional Cancer Imaging. Dr. François Bénard is cofounder, director, and shareholder of Alpha-9 Theranostics, a radiopharmaceutical company. No other potential conflict of interest relevant to this article was reported.

QUESTION: Does orally administered MSG reduce kidney and salivary gland radiation exposure when a PSMA-targeting radiotracer is used in human subjects?

PERTINENT FINDINGS: In this analysis of a prospective, randomized, double-blind, placebo-controlled intraindividual trial, MSG significantly reduced SUL$_{max}$ in the parotids (24% ± 14%), submandibular glands (35% ± 11%), and kidneys (23% ± 26%), with no adverse events.

IMPLICATIONS FOR PATIENT CARE: MSG is a candidate compound for kidney and salivary gland protection during PSMA-targeting RLT.

REFERENCES